Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 29;4(2):e350.
doi: 10.1002/ski2.350. eCollection 2024 Apr.

Effectiveness of sequential lines of biologic and targeted small molecule drugs in psoriasis: A systematic review and meta-analysis

Charlotte E Gollins  1   2 , Rosie Vincent  1   3 , Caoimhe Fahy  1 , Neil McHugh  2 , William Tillett  2   4
Affiliations

Effectiveness of sequential lines of biologic and targeted small molecule drugs in psoriasis: A systematic review and meta-analysis

Charlotte E Gollins et al. Skin Health Dis. .

Abstract

To assess current evidence of effectiveness of sequential lines of biologic and targeted small molecule drugs for psoriasis beyond first line. A systematic search of the literature (Medline, Embase and bibliographic) was undertaken in October and December 2022 to find all studies assessing effectiveness of biologics and targeted small molecules when used beyond first-line in adults with psoriasis (PROSPERO CRD42022365298). Data extraction and a bias assessment (Risk Of Bias In Non-randomized Studies-of Interventions/Cochrane RoB2) were undertaken for all included studies. A random effects proportional meta-analysis was undertaken for PASI75/90/100 at 12-16 weeks for each line of treatment (1st to 4th). Of 2666 abstracts identified, a full text review was undertaken of 177 studies; 20 manuscripts met eligibility criteria. Twenty studies were included in the analysis: 19 observational studies and one sub analysis of a RCT; n = 6495 (average age 49.7 years, female 35.1%). Eleven studies assessed second line biologic, nine assessed third + line. A meta-analysis of PASI75 at 12-16 weeks found pooled effect percentage achieving PASI75 of 61%, 56%, 79% and 61% in 1st, 2nd, 3rd and 4th line biologics respectively. Meta-analyses of PASI90/100 also found no evidence of diminished effectiveness with sequential lines (PASI90 46.1%, 39.9%, 55.8% and 33.7% and PASI100 36.7%, 30.3%, 46.7% and 30.4% in 1st to 4th line respectively). Available evidence for effectiveness of biologics beyond first line in psoriasis is predominantly observational, at high risk of bias and of low quality. There is very limited data for effectiveness beyond second line. Evidence indicates that biologics can be effective to fourth-line.

PubMed Disclaimer

Conflict of interest statement

WRT has received research funding, speaker fees or honoraria from Abbvie, Amgen, Eli‐Lilly, GSK, Janssen, MSD, Novartis, Ono‐Pharma, Pfizer and UCB. CF has received honararia (speaker fees) from Pfizer and Eli Lilly. NJM has received a grant for unrelated work from UCB, honoraria (speaker fee) from Janssen and participated in data monitoring and safety in the NIHR HTA Astute trial. RV has received payment to her institution (speaker fees) from Leo Pharma and funding from Dermal to attend an educational event. CG has no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Study selection flow diagram for systematic review.
FIGURE 2
FIGURE 2
The number of patients reported in the included literature by line of biologic or targeted small molecule drug.
FIGURE 3
FIGURE 3
(a) Meta‐analysis of PASI75 at 12–16 weeks for 1st and 2nd line. (b) Meta‐analysis of PASI75 at 12–16 weeks for 3rd and 4th line.
FIGURE 3
FIGURE 3
(a) Meta‐analysis of PASI75 at 12–16 weeks for 1st and 2nd line. (b) Meta‐analysis of PASI75 at 12–16 weeks for 3rd and 4th line.
FIGURE 4
FIGURE 4
Meta‐analysis of PASI90 at 12–16 weeks for 1st to 4th line.
FIGURE 5
FIGURE 5
Meta‐analysis of PASI100 at 12–16 weeks for 1st–4th line.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization . Global report on psoriasis. [Internet]. 2016. [cited 2023 Apr 1]. Available from: https://www.who.int/publications/i/item/9789241565189
    1. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ (Online). 2020;369:m1590. 10.1136/bmj.m1590 - DOI - PMC - PubMed
    1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017;376(10):957–970. 10.1056/nejmra1505557 - DOI - PubMed
    1. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704–708. 10.1016/j.jaad.2004.04.014 - DOI - PubMed
    1. Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep. 2012;14(4):369–374. 10.1007/s11926-012-0263-5 - DOI - PubMed

LinkOut - more resources